Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer

Exclusion Criteria

• •1. Pathology confirmed with sarcoma components (including malignant mixed mullerian tumors, endometrial leiomyosarcoma, and endometrial stromal sarcoma);
• •2. Patients who have previously received albumin-bound paclitaxel or exposures to any anti-PD-1 antibody drugs;
• •3. Exposures to any anti-tumor drugs within 4 weeks;
• •4. Current or prior use of any immunosuppressive medication or systemic hormone therapy（which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid Prednisone\>10mg/d）within 14 days before the first dose of anti-PD-1 antibody;
• •5. Any primary malignancy within 5 years (except for fully treated in situ malignant such as breast cancer, bladder cancer, cervical carcinoma in situ, cutaneous basal cell carcinoma or squamous cell carcinoma);
• •6. History of psychiatric drugs abuse and not be abstinent, or dysphrenia；
• •7. Central nervous system diseases, including uncontrollable epilepsy and symptomatic brain metastases;
• •8. Severe cardiovascular disease: unstable angina pectoris, myocardial infarction, grade III-IV cardiac insufficiency (NYHA standard), and peripheral vascular disease above 2 degrees within 6 months prior to enrollment;
• •9. Severe arrhythmia requiring drug control, QT interval \>470ms；
• •10. Active infections such as HIV/AIDS or other serious infectious diseases;
• •11. Any active autoimmune disease or history of autoimmune disease (including but not limit to autoimmune hepatitis, interstitial pneumonia, hepatitis, enteritis, nephritis, hyperthyroidism, pituitary inflammation, vasculitis, uveitis) . Patients need receiving systemic hormonal therapy and/or immunosuppressive therapy (eg asthma requiring bronchodilators);
• •12. Receipt of live attenuated vaccination within 30 days prior to study entry;
• •13. Other conditions regimented at investigators' discretion.